MATRIX RELOADED: Doctors Try New Techniques To Regrow Human Tissue
By Ron Winslow,
Wall Street Journal
| 02. 12. 2007
Five soldiers at a military base in Texas are about to participate in a remarkable test to see if they can regrow portions of fingers they lost in the war in Iraq.
Doctors plan to treat them with a fine powder called extracellular matrix, harvested from pig bladders. The material, found in all animals, is the scaffolding that cells latch onto as they divide and grow into tissue and body parts. In the human body, it was long thought to be inert. But scientists have discovered that it appears to activate latent biological processes that spur healing and regenerate tissue.
Medical researchers have been making intriguing progress in the field of regenerative medicine. The pilot test in Texas shows how doctors are trying to apply their recent discoveries to a pressing challenge: helping thousands of Americans returning from Iraq to recover from wounds that would have killed soldiers a generation ago.
Scientists have long been enthralled by the ability of animals such as salamanders, starfish and deer to regrow body parts lost due to injury or other causes. Cut off...
Related Articles
Not the species, certainly, but the Institute of that name, which was founded by transhumanist philosopher Nick Bostrom in 2005 as a research group at Oxford University. According to a recently posted Final Report, its goal was “to pursue the big questions in a transdisciplinary way” by pulling together “researchers from disciplines such as philosophy, computer science, mathematics, and economics.” This evolved before long into the study and promotion of “effective altruism” and “longtermism” as...
By Yelena Biberman and Jonathan D. Moreno, Bioethics Forum | 04.16.2024
A quiet biological revolution in warfare is underway. The genome is emerging as a new domain of conflict. The level of destruction that only nuclear weapons could previously achieve is fast becoming as accessible as a cyberattack.
Now for the...
By Tristan Manalac, BioSpace | 04.02.2024
Verve Therapeutics has suspended enrollment in the Phase Ib Heart-1 study evaluating its lead gene editing program VERVE-101 following a serious adverse event, the company announced Tuesday.
A patient, who received a 0.45-mg/kg dose of VERVE-101, developed a grade 3...
By Timnit Gebru and Émile P. Torres, First Monday | 04.14.2024
The stated goal of many organizations in the field of artificial intelligence (AI) is to develop artificial general intelligence (AGI), an imagined system with more intelligence than anything we have ever seen. Without seriously questioning whether such a system can...